DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: paclitaxel

Summary for Generic Name: paclitaxel

Tradenames:3
Patents:8
Applicants:13
NDAs:14
Drug Master File Entries: see list63
Suppliers: see list2
Formulation / Manufacturing:see details

Pharmacology for Ingredient: paclitaxel

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition

Clinical Trials for: paclitaxel

Hepatic Arterial Infusion (HAI) of Abraxane
Status: Active, not recruiting Condition: Liver Cancer; Advanced Cancers; Solid Tumors

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Status: Active, not recruiting Condition: Breast Cancer

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Status: Recruiting Condition: Resectable Pancreatic Adenocarcinoma

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Status: Recruiting Condition: Bladder Cancer

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
Status: Completed Condition: Urothelial Cancer; Bladder Cancer

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Status: Active, not recruiting Condition: Metastatic Breast Cancer

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Status: Recruiting Condition: Advanced Cancer

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Status: Terminated Condition: Breast Neoplasms; Neoplasm Metastasis

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Status: Recruiting Condition: Melanoma

HAI Abraxane With Gemcitabine and Bevacizumab
Status: Completed Condition: Advanced Cancers

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes7,820,788<disabled>YTREATMENT OF LUNG CANCER
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes7,820,788<disabled>YTREATMENT OF BREAST CANCER
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes7,923,536<disabled>TREATMENT OF LUNG CANCER
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660Jan 7, 2005RXYes7,923,536<disabled>TREATMENT OF BREAST CANCER
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc